---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-020619"
form_type: "8-K"
ticker: null
cik: "0001358403"
company_name: "BELLICUM PHARMACEUTICALS, INC"
filed_at: "2023-06-02T23:59:59+00:00"
generated_at: "2026-06-14T08:04:39.775682+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Bellicum Pharma terminates CEO Richard Fair and CDO Charity Scripture; effective June 30, 2023

## Summary
- CEO Richard Fair and CDO Charity Scripture notified on May 31 that employment ends June 30, 2023.
- Both receive severance per agreements; Scripture gets COBRA reimbursement for up to 12 months.
- Both will sign consulting agreements to continue as officers as consultants on hourly basis.
- Severance conditioned on providing a general release of claims for the company.

## SEC filing metadata
- accession: 0001628280-23-020619
- form_type: 8-K
- cik: 0001358403
- company_name: BELLICUM PHARMACEUTICALS, INC
- filed_at: 2023-06-02T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1358403/000162828023020619/0001628280-23-020619-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1358403/000162828023020619/blcm-20230602.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-020619
- JSON: https://secwatch.observer/filing/0001628280-23-020619.json
- Plain text: https://secwatch.observer/filing/0001628280-23-020619.txt

## Key facts
- Executive change
  Richard Fair was terminated as President and Chief Executive Officer at BELLICUM PHARMACEUTICALS, INC.
  - Action: terminated
  - Role: President and Chief Executive Officer
  source text: On May 31, 2023, the Company provided notices to Richard Fair, President and Chief Executive Officer, and Charity Scripture, Chief Development Officer that their employment by the Company will terminate on June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1358403/000162828023020619/0001628280-23-020619-index.htm
- Executive change
  Charity Scripture was terminated as Chief Development Officer at BELLICUM PHARMACEUTICALS, INC.
  - Action: terminated
  - Role: Chief Development Officer
  source text: On May 31, 2023, the Company provided notices to Richard Fair, President and Chief Executive Officer, and Charity Scripture, Chief Development Officer that their employment by the Company will terminate on June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1358403/000162828023020619/0001628280-23-020619-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.